▶ FRAG 176-191 · SUBTOPIC · DOSING LITERATURE
FRAG 176-191 Dosing Literature
For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.
SCOPE OF THIS PAGE
This page documents the published-literature dose ranges that appear in trials and animal studies of FRAG 176-191. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.
ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH
The published research record for FRAG 176-191 reports the following route(s) of administration: Subcutaneous (research). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of FRAG 176-191.
PHARMACOKINETIC HALF-LIFE
Published pharmacokinetic data report a half-life for FRAG 176-191 of approximately ~30 minutes (rapid plasma clearance). Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.
CITED DOSE RANGES IN THE LITERATURE
The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of FRAG 176-191. Refer to the original publication for full protocol detail.
- Ng FM, Sun J, Sharma L, et al. (2000) reports the FRAG 176-191 protocol used in Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone, published in Horm Res. PMID 10681682. See the source for the protocol-level dose range, frequency, and duration. link
- Stier H, Vos E, Kenley D (2013) reports the FRAG 176-191 protocol used in Safety and tolerability of the hexadecapeptide AOD9604 in humans, published in J Endocrinol Invest. See the source for the protocol-level dose range, frequency, and duration. link
DOSING Q+A FROM LITERATURE
The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.
▶ What is the half-life of Frag 176-191?
Approximately 30 minutes plasma half-life. Daily subcutaneous administration is the standard research protocol.
STORAGE OF THE REFERENCE COMPOUND
Lyophilized · 2-8 °C, 24 months
Reconstituted · 2-8 °C, 28 days
Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.
RECONSTITUTION MATH (CALCULATOR)
The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.
REGULATORY CONTEXT
FDA · Not FDA-approved. Research-use only.
WADA · Not currently listed on the WADA Prohibited List (2026). Status reviewable annually.
RELATED PAGES
▶ LAST UPDATED · 2026-05-25